Noble Financial Has Positive Outlook of CVKD FY2025 Earnings

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Equities research analysts at Noble Financial increased their FY2025 earnings per share estimates for shares of Cadrenal Therapeutics in a report issued on Tuesday, November 11th. Noble Financial analyst R. Leboyer now expects that the company will earn ($6.37) per share for the year, up from their previous estimate of ($7.19). The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($7.59) per share. Noble Financial also issued estimates for Cadrenal Therapeutics’ Q4 2025 earnings at ($1.21) EPS, Q1 2026 earnings at ($1.33) EPS, Q2 2026 earnings at ($1.39) EPS, Q3 2026 earnings at ($1.51) EPS and Q4 2026 earnings at ($1.23) EPS.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $32.00.

Cadrenal Therapeutics Stock Performance

Shares of CVKD stock traded up $0.05 on Thursday, hitting $12.29. 4,702 shares of the company’s stock traded hands, compared to its average volume of 31,044. The company’s fifty day simple moving average is $13.31 and its 200 day simple moving average is $13.20. The stock has a market capitalization of $25.55 million, a price-to-earnings ratio of -1.53 and a beta of 0.96. Cadrenal Therapeutics has a one year low of $8.74 and a one year high of $22.90.

Cadrenal Therapeutics (NASDAQ:CVKD) last posted its quarterly earnings results on Monday, November 10th. The company reported ($1.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.55) by $0.24.

Insiders Place Their Bets

In related news, CEO Quang X. Pham sold 1,800 shares of the firm’s stock in a transaction dated Monday, October 13th. The stock was sold at an average price of $14.15, for a total transaction of $25,470.00. Following the sale, the chief executive officer directly owned 198,533 shares of the company’s stock, valued at $2,809,241.95. This trade represents a 0.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Matthew K. Szot sold 1,800 shares of Cadrenal Therapeutics stock in a transaction dated Monday, October 27th. The stock was sold at an average price of $13.99, for a total value of $25,182.00. Following the completion of the sale, the chief financial officer owned 9,933 shares in the company, valued at approximately $138,962.67. The trade was a 15.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 45,644 shares of company stock valued at $640,540 over the last three months. Insiders own 26.09% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cadrenal Therapeutics stock. JPMorgan Chase & Co. bought a new position in shares of Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 7,500 shares of the company’s stock, valued at approximately $103,000. JPMorgan Chase & Co. owned approximately 0.37% of Cadrenal Therapeutics at the end of the most recent quarter. Institutional investors own 7.92% of the company’s stock.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.